Baseline Fractional Flow Reserve and Stent Diameter Predict Event Rates After Stenting. A Further Step, But Still Much to Learn

JACC: Cardiovascular Interventions

Volumn 2, Issue 4, 2009, Pages 364-365

  Leesar, Massoud A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

bare metal stent; drug eluting stent; fractional flow reserve; percutaneous coronary intervention

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

ANGIOCARDIOGRAPHY; BARE METAL STENT; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; EDITORIAL; FRACTIONAL FLOW RESERVE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HUMANS; METALS; PREDICTIVE VALUE OF TESTS; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 64749112124     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.02.004     Document Type: Editorial

References (9)

1. Pijls N.H.J., van Schaardenburgh P., Manoharan G., et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 49 (2007) 2105-2111
2. Pijls N.H.J., Klauss V., Siebert U., et al. Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. Circulation 105 (2002) 2950-2954
3. Samady H., McDaniel M., and Veledar E. Baseline fractional flow reserve and stent diameter predict optimal post-stent fractional flow reserve and major adverse cardiac events after bare metal stent deployment. J Am Coll Cardiol Intv 2 (2009) 357-363
4. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
5. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al., BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
6. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
7. Mintz G.S., Popma J., Pichard A., et al. Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization. J Am Coll Cardiol 27 (1996) 1678-1687
8. Hanekamp C., Koolen J.J., Pijls N.H.J., et al. Comparison of quantitative coronary angiography, intravascular ultrasound and pressure-derived fractional flow reserve to assess optimal stent deployment. Circulation 99 (1999) 1015-1021
9. De Bruyne B., Hersbach F., Pijls N.H.J., et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "normal" coronary angiography. Circulation 104 (2001) 2401-2406